Abstract 18342: Matrix Metalloproteinase-9 is Independently Associated with Aortic Wall Thickness: from the Dallas Heart Study
Background: Matrix metalloproteinase-9 (MMP-9) is an endopeptidase active in the extracellular matrix. Prior reports have associated increased circulating levels of MMP-9 with abdominal aortic pathology, including formation and rupture of aortic aneurysms, raising the possibility that MMP-9 may be a useful diagnostic or therapeutic target for aortic pathology. However, the association between MMP-9 and abdominal aortic phenotype in the general population has not been reported.
Methods: In the Dallas Heart Study, a large multi-ethnic probability based population sample of Dallas County residents aged 30–65, we measured plasma MMP-9 and performed detailed MRI phenotyping of the abdominal aorta including measurement of aortic compliance (AC), plaque (AP) and wall thickness (AWT) (n = 2,307). Differences in cardiac risk factors, metabolic and body size factors, and the three MRI measurements across quartiles of MMP-9 were determined and linear regression analyses for AWT as a function of log[MMP-9] were performed with and without adjustment for age, diabetes, smoking, hypertension, cholesterol, sex, race, and BMI.
Results: Increasing MMP-9 was associated with traditional cardiovascular risk factors, larger BMI (p < 0.0001), metabolic syndrome (p < 0.0001), insulin resistance (HOMA-IR, p < 0.0001) and hsCRP (p < 0.0001). In unadjusted analyses, increasing MMP-9 was associated with AWT (p<0.0001, Figure) but not AC (p = 0.5). There was a trend toward association between increasing MMP-9 and both the presence of detectable AP (p = 0.070) and total AP burden (p=0.041).MMP-9 remained independently associated with AWT after multivariable adjustment (p=0.004).
Conclusion: In this large, ethnically diverse population-based cohort with detailed aortic phenotyping by MRI, plasma levels of MMP-9 were independently associated with aortic wall thickness, supporting the hypothesis that therapies targeting MMP-9 may have an effect on the abdominal aortic wall.
- © 2010 by American Heart Association, Inc.